ArticleFrontiers in psychiatry2026
Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have been shown to predict the clinical effects of psilocybin treatment in depression, anxiety, and addiction. However, no studies have examined whether acute subjective experiences predict treatment response in obsessive-compulsive disorder (OCD). Methods: Exploratory analyses were conducted using data from participants with treatment-resistant OCD who received psilocybin as part of a randomized, double-blind, placebo-controlled trial and subsequent open-label phase. Twenty-seven participants who received psilocybin (0.25 mg/kg) completed the Mystical Experience Questionnaire (MEQ-30) and Challenging Experience Questionnaire (CEQ) the day following their session. OCD severity was assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at baseline and at 1- and 12-week follow-up. Results: Greater mystical-type experiences during psilocybin were associated with lower OCD symptom severity at 1- and 12-week follow-up, even after controlling for baseline OCD symptom severity and treatment condition. The Mystical subscale demonstrated the strongest and most consistent associations at both time points, while the Space-Time subscale was only associated with lower Y-BOCS at 12 weeks. The Positive Mood and Ineffability subscales were not significantly associated with post-treatment OCD symptom severity after correction for multiple comparisons. Challenging experiences were not significantly associated with post-treatment OCD severity. Conclusions: Mystical experiences - particularly experiences of unity, sacredness, and transcendence - during psilocybin sessions are associated with greater OCD symptom reduction. These findings support attention to experiential quality in psilocybin-assisted therapy and have implications for optimizing treatment through dosing, set, setting, and integration practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.